Treatment strategy at the decision for allogeneic transplantation in patients with myelodysplastic syndrome in the era of azacitidine : A KSGCT prospective study
Copyright © 2023 Elsevier Ltd. All rights reserved..
The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We performed a prospective observational study in which 110 patients with MDS who were decided to undergo HSCT were enrolled. Among these 110 patients, 77 patients were enrolled in this study within 1 month from the decision for HSCT. Among these 77 patients, 13 patients had a human leukocyte antigen (HLA)-matched sibling, 54 patients started an unrelated donor search, and the other 10 patients directly selected cord blood (CB) at the decision for HSCT, and 13 (100%), 38 (70.4%), and 9 (90%) patients actually underwent HSCT within 1 year, respectively. The overall survival (OS) at 1 year from their enrollment was 70.9%, and the selection of azacitidine use at the decision for HSCT was not associated with OS. Among 60 of the 77 patients who actually underwent HSCT within a year from their enrollment, a lower relapse rate after HSCT was observed in those who selected CB at the decision to undergo HSCT. However, this preferable effect of CB selection disappeared when patients who were enrolled in this study in > 1 month from the decision for HSCT were additionally included in the analyses. In conclusion, the selection of bridge strategy at the decision for HSCT did not affect outcomes in patients with MDS. The immediate performance of HSCT may be associated with better outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
Leukemia research - 133(2023) vom: 14. Okt., Seite 107371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kako, Shinichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogeneic transplantation |
|---|
| Anmerkungen: |
Date Completed 02.10.2023 Date Revised 11.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.leukres.2023.107371 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360941672 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360941672 | ||
| 003 | DE-627 | ||
| 005 | 20231226084108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2023.107371 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360941672 | ||
| 035 | |a (NLM)37595372 | ||
| 035 | |a (PII)S0145-2126(23)00636-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kako, Shinichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment strategy at the decision for allogeneic transplantation in patients with myelodysplastic syndrome in the era of azacitidine |b A KSGCT prospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.10.2023 | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a The optimal bridge strategy at the decision for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelodysplastic syndrome (MDS) is unclear. We performed a prospective observational study in which 110 patients with MDS who were decided to undergo HSCT were enrolled. Among these 110 patients, 77 patients were enrolled in this study within 1 month from the decision for HSCT. Among these 77 patients, 13 patients had a human leukocyte antigen (HLA)-matched sibling, 54 patients started an unrelated donor search, and the other 10 patients directly selected cord blood (CB) at the decision for HSCT, and 13 (100%), 38 (70.4%), and 9 (90%) patients actually underwent HSCT within 1 year, respectively. The overall survival (OS) at 1 year from their enrollment was 70.9%, and the selection of azacitidine use at the decision for HSCT was not associated with OS. Among 60 of the 77 patients who actually underwent HSCT within a year from their enrollment, a lower relapse rate after HSCT was observed in those who selected CB at the decision to undergo HSCT. However, this preferable effect of CB selection disappeared when patients who were enrolled in this study in > 1 month from the decision for HSCT were additionally included in the analyses. In conclusion, the selection of bridge strategy at the decision for HSCT did not affect outcomes in patients with MDS. The immediate performance of HSCT may be associated with better outcomes | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allogeneic transplantation | |
| 650 | 4 | |a Azacitidine | |
| 650 | 4 | |a Myelodysplastic syndrome | |
| 650 | 4 | |a Transplantation decision | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Kimura, Shun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Wada, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Komiya, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakasone, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Sakurai, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Masatsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Eriko |e verfasserin |4 aut | |
| 700 | 1 | |a Tachibana, Takayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Wataru |e verfasserin |4 aut | |
| 700 | 1 | |a Hagihara, Maki |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Reiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yokota, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Takehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakaseko, Chiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kanamori, Heiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Yoshinobu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia research |d 1991 |g 133(2023) vom: 14. Okt., Seite 107371 |w (DE-627)NLM000939560 |x 1873-5835 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2023 |g day:14 |g month:10 |g pages:107371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.leukres.2023.107371 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2023 |b 14 |c 10 |h 107371 | ||